Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | CASR | P41180 | 2/20 | 0.36 |
| ▸ | PPIB | P23284 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29930766 | 0.93 | LMNA (0.42) | LMNAKMT2AATMHCAR2TRPV1 | |
| SCHEMBL23327453 | 0.93 | LMNA (0.42) | LMNAKMT2AATMHCAR2TRPV1 | |
| SCHEMBL23327491 | 0.86 | TRPV1 (0.46) | KMT2ATRPV1MAPK1CNR1FPR2 | |
| SCHEMBL23327703 | 0.84 | KDM4E (0.36) | KMT2ATRPV1MAPK1MAPT | |
| SCHEMBL23327537 | 0.83 | NR3C2 (0.38) | KMT2A | |
| SCHEMBL23327500 | 0.78 | ALDH1A1 (0.43) | KMT2AMAPT | |
| SCHEMBL23351205 | 0.77 | ALDH1A1 (0.35) | LMNAKMT2A | |
| SCHEMBL26098304 | 0.75 | PTPN1 (0.49) | KMT2AMAPT | |
| SCHEMBL21811192 | 0.72 | KDM4E (0.44) | LMNAMAPT | |
| SCHEMBL23327454 | 0.70 | MAPT (0.42) | LMNAMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | VENTYX BIOSCIENCES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210139486-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | TYK2, JAK1, JAK2 | LMNA 2097/4885KMT2A 819/4885ATM 494/4885 |
| US-20210139486-A1 | TYK2 PSEUDOKINASE LIGANDS | TYK2, JAK2, PTK2B | LMNA 2091/4885KMT2A 901/4885ATM 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.